E
Alaunos Therapeutics, Inc.
TCRT
$1.50
-$0.04-2.60%
E
Sell
9/18/2023Downgrade
Alaunos Therapeutics, Inc. (TCRT) was downgraded to E+ from D- on 9/18/2023 due to a decline in the volatility index.
Alaunos Therapeutics, Inc. (TCRT) was downgraded to E+ from D- on 9/18/2023 due to a decline in the volatility index.
D
Sell
9/1/2023Upgraded
Alaunos Therapeutics, Inc. (TCRT) was upgraded to D- from E+ on 9/1/2023 due to an increase in the valuation index and volatility index.
Alaunos Therapeutics, Inc. (TCRT) was upgraded to D- from E+ on 9/1/2023 due to an increase in the valuation index and volatility index.
E
Sell
8/17/2023Downgrade
Alaunos Therapeutics, Inc. (TCRT) was downgraded to E+ from D- on 8/17/2023 due to a decline in the valuation index, volatility index and total return index.
Alaunos Therapeutics, Inc. (TCRT) was downgraded to E+ from D- on 8/17/2023 due to a decline in the valuation index, volatility index and total return index.
D
Sell
8/14/2023Upgraded
Alaunos Therapeutics, Inc. (TCRT) was upgraded to D- from E+ on 8/14/2023 due to an increase in the volatility index and valuation index.
Alaunos Therapeutics, Inc. (TCRT) was upgraded to D- from E+ on 8/14/2023 due to an increase in the volatility index and valuation index.
E
Sell
3/14/2023Downgrade
Alaunos Therapeutics, Inc. (TCRT) was downgraded to E+ from D on 3/14/2023 due to a decline in the volatility index and total return index.
Alaunos Therapeutics, Inc. (TCRT) was downgraded to E+ from D on 3/14/2023 due to a decline in the volatility index and total return index.
D
Sell
2/9/2023Upgraded
Alaunos Therapeutics, Inc. (TCRT) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index, valuation index and total return index.
Alaunos Therapeutics, Inc. (TCRT) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index, valuation index and total return index.
E
Sell
2/8/2023Downgrade
Alaunos Therapeutics, Inc. (TCRT) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index and total return index.
Alaunos Therapeutics, Inc. (TCRT) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index and total return index.
D
Sell
2/6/2023Upgraded
Alaunos Therapeutics, Inc. (TCRT) was upgraded to D from D- on 2/6/2023 due to an increase in the valuation index and volatility index.
Alaunos Therapeutics, Inc. (TCRT) was upgraded to D from D- on 2/6/2023 due to an increase in the valuation index and volatility index.
D
Sell
1/20/2023Downgrade
Alaunos Therapeutics, Inc. (TCRT) was downgraded to D- from D on 1/20/2023 due to a decline in the total return index.
Alaunos Therapeutics, Inc. (TCRT) was downgraded to D- from D on 1/20/2023 due to a decline in the total return index.
D
Sell
7/22/2022Upgraded
Alaunos Therapeutics, Inc. (TCRT) was upgraded to D from D- on 7/22/2022 due to an increase in the total return index and volatility index.
Alaunos Therapeutics, Inc. (TCRT) was upgraded to D from D- on 7/22/2022 due to an increase in the total return index and volatility index.
D
Sell
6/21/2022Downgrade
Alaunos Therapeutics, Inc. (TCRT) was downgraded to D- from D on 6/21/2022 due to a decline in the volatility index and valuation index.
Alaunos Therapeutics, Inc. (TCRT) was downgraded to D- from D on 6/21/2022 due to a decline in the volatility index and valuation index.
D
Sell
6/6/2022Upgraded
Alaunos Therapeutics, Inc. (TCRT) was upgraded to D from D- on 6/6/2022 due to an increase in the volatility index.
Alaunos Therapeutics, Inc. (TCRT) was upgraded to D from D- on 6/6/2022 due to an increase in the volatility index.
D
Sell
5/19/2022Downgrade
Alaunos Therapeutics, Inc. (TCRT) was downgraded to D- from D on 5/19/2022 due to a decline in the growth index and volatility index.
Alaunos Therapeutics, Inc. (TCRT) was downgraded to D- from D on 5/19/2022 due to a decline in the growth index and volatility index.
D
Sell
5/16/2022Upgraded
Alaunos Therapeutics, Inc. (TCRT) was upgraded to D from E+ on 05/16/2022.
Alaunos Therapeutics, Inc. (TCRT) was upgraded to D from E+ on 05/16/2022.
E
Sell
5/13/2022Downgrade
Alaunos Therapeutics, Inc. (TCRT) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index and valuation index.
Alaunos Therapeutics, Inc. (TCRT) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index and valuation index.
D
Sell
5/4/2022Upgraded
Alaunos Therapeutics, Inc. (TCRT) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
Alaunos Therapeutics, Inc. (TCRT) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
E
Sell
5/1/2022Downgrade
Alaunos Therapeutics, Inc. (TCRT) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index.
Alaunos Therapeutics, Inc. (TCRT) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index.
D
Sell
4/21/2022Upgraded
Alaunos Therapeutics, Inc. (TCRT) was upgraded to D from E+ on 04/21/2022.
Alaunos Therapeutics, Inc. (TCRT) was upgraded to D from E+ on 04/21/2022.
E
Sell
4/20/2022Downgrade
Alaunos Therapeutics, Inc. (TCRT) was downgraded to E+ from D on 4/20/2022 due to a decline in the total return index and volatility index.
Alaunos Therapeutics, Inc. (TCRT) was downgraded to E+ from D on 4/20/2022 due to a decline in the total return index and volatility index.
D
Sell
3/31/2022Upgraded
Alaunos Therapeutics, Inc. (TCRT) was upgraded to D from D- on 3/31/2022 due to a major increase in the growth index and valuation index. Earnings per share increased from -$0.106 to -$0.0576, and EBIT increased 44.7% from -$21M to -$11.61M.
Alaunos Therapeutics, Inc. (TCRT) was upgraded to D from D- on 3/31/2022 due to a major increase in the growth index and valuation index. Earnings per share increased from -$0.106 to -$0.0576, and EBIT increased 44.7% from -$21M to -$11.61M.
D
Sell
11/9/2021Upgraded
Alaunos Therapeutics, Inc. (TCRT) was upgraded to D- from E+ on 11/09/2021.
Alaunos Therapeutics, Inc. (TCRT) was upgraded to D- from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
ZIOPHARM Oncology, Inc. (ZIOP) was downgraded to E+ from D- on 11/8/2021 due to a decline in the total return index.
ZIOPHARM Oncology, Inc. (ZIOP) was downgraded to E+ from D- on 11/8/2021 due to a decline in the total return index.
D
Sell
9/16/2021Downgrade
ZIOPHARM Oncology, Inc. (ZIOP) was downgraded to D- from D on 9/16/2021 due to a decline in the valuation index, total return index and volatility index.
ZIOPHARM Oncology, Inc. (ZIOP) was downgraded to D- from D on 9/16/2021 due to a decline in the valuation index, total return index and volatility index.
D
Sell
9/1/2021Upgraded
ZIOPHARM Oncology, Inc. (ZIOP) was upgraded to D from D- on 9/1/2021 due to an increase in the valuation index.
ZIOPHARM Oncology, Inc. (ZIOP) was upgraded to D from D- on 9/1/2021 due to an increase in the valuation index.
D
Sell
8/17/2021Downgrade
ZIOPHARM Oncology, Inc. (ZIOP) was downgraded to D- from D on 8/17/2021 due to a noticeable decline in the total return index, volatility index and solvency index.
ZIOPHARM Oncology, Inc. (ZIOP) was downgraded to D- from D on 8/17/2021 due to a noticeable decline in the total return index, volatility index and solvency index.
D
Sell
2/4/2021Upgraded
ZIOPHARM Oncology, Inc. (ZIOP) was upgraded to D from D- on 2/4/2021 due to an increase in the volatility index and total return index.
ZIOPHARM Oncology, Inc. (ZIOP) was upgraded to D from D- on 2/4/2021 due to an increase in the volatility index and total return index.
D
Sell
10/8/2020Downgrade
ZIOPHARM Oncology, Inc. (ZIOP) was downgraded to D- from D on 10/8/2020 due to a decline in the volatility index.
ZIOPHARM Oncology, Inc. (ZIOP) was downgraded to D- from D on 10/8/2020 due to a decline in the volatility index.
D
Sell
9/8/2020Upgraded
ZIOPHARM Oncology, Inc. (ZIOP) was upgraded to D from D- on 9/8/2020 due to an increase in the valuation index, total return index and volatility index.
ZIOPHARM Oncology, Inc. (ZIOP) was upgraded to D from D- on 9/8/2020 due to an increase in the valuation index, total return index and volatility index.
D
Sell
8/7/2020Downgrade
ZIOPHARM Oncology, Inc. (ZIOP) was downgraded to D- from D on 8/7/2020 due to a decline in the growth index, solvency index and valuation index. Operating cash flow declined 41.39% from -$9.91M to -$14.01M, and the quick ratio declined from 10.36 to 9.21.
ZIOPHARM Oncology, Inc. (ZIOP) was downgraded to D- from D on 8/7/2020 due to a decline in the growth index, solvency index and valuation index. Operating cash flow declined 41.39% from -$9.91M to -$14.01M, and the quick ratio declined from 10.36 to 9.21.
D
Sell
6/19/2020Upgraded
ZIOPHARM Oncology, Inc. (ZIOP) was upgraded to D from D- on 6/19/2020 due to an increase in the volatility index.
ZIOPHARM Oncology, Inc. (ZIOP) was upgraded to D from D- on 6/19/2020 due to an increase in the volatility index.
D
Sell
12/26/2019Downgrade
ZIOPHARM Oncology, Inc. (ZIOP) was downgraded to D- from D on 12/26/2019 due to a large decline in the solvency index, valuation index and volatility index.
ZIOPHARM Oncology, Inc. (ZIOP) was downgraded to D- from D on 12/26/2019 due to a large decline in the solvency index, valuation index and volatility index.
D
Sell
4/11/2019Upgraded
ZIOPHARM Oncology, Inc. (ZIOP) was upgraded to D from D- on 4/11/2019 due to a significant increase in the valuation index, solvency index and growth index. The quick ratio increased from 0.54 to 6.71, and earnings per share increased from -$0.1322 to $1.2892.
ZIOPHARM Oncology, Inc. (ZIOP) was upgraded to D from D- on 4/11/2019 due to a significant increase in the valuation index, solvency index and growth index. The quick ratio increased from 0.54 to 6.71, and earnings per share increased from -$0.1322 to $1.2892.
D
Sell
8/2/2018Downgrade
ZIOPHARM Oncology, Inc. (ZIOP) was downgraded to D- from D on 8/2/2018 due to a decline in the total return index.
ZIOPHARM Oncology, Inc. (ZIOP) was downgraded to D- from D on 8/2/2018 due to a decline in the total return index.
D
Sell
5/16/2018Upgraded
ZIOPHARM Oncology, Inc. (ZIOP) was upgraded to D from D- on 5/16/2018 due to an increase in the efficiency index and growth index.
ZIOPHARM Oncology, Inc. (ZIOP) was upgraded to D from D- on 5/16/2018 due to an increase in the efficiency index and growth index.
D
Sell
5/2/2017Downgrade
ZIOPHARM Oncology, Inc. (ZIOP) was downgraded to D- from D on 5/2/2017 due to a decline in the growth index, total return index and efficiency index. Net income declined 37.98% from -$11.22M to -$15.49M, earnings per share declined from -$0.1131 to -$0.1504, and total capital declined 28.08% from $48.02M to $34.54M.
ZIOPHARM Oncology, Inc. (ZIOP) was downgraded to D- from D on 5/2/2017 due to a decline in the growth index, total return index and efficiency index. Net income declined 37.98% from -$11.22M to -$15.49M, earnings per share declined from -$0.1131 to -$0.1504, and total capital declined 28.08% from $48.02M to $34.54M.
D
Sell
1/17/2017Upgraded
ZIOPHARM Oncology, Inc. (ZIOP) was upgraded to D from D- on 1/17/2017 due to an increase in the volatility index and total return index.
ZIOPHARM Oncology, Inc. (ZIOP) was upgraded to D from D- on 1/17/2017 due to an increase in the volatility index and total return index.
D
Sell
12/27/2016Downgrade
ZIOPHARM Oncology, Inc. (ZIOP) was downgraded to D- from D on 12/27/2016 due to a decline in the volatility index.
ZIOPHARM Oncology, Inc. (ZIOP) was downgraded to D- from D on 12/27/2016 due to a decline in the volatility index.
D
Sell
11/10/2016Upgraded
ZIOPHARM Oncology, Inc. (ZIOP) was upgraded to D from D- on 11/10/2016 due to an increase in the growth index and efficiency index. Net income increased 91.73% from -$131.2M to -$10.85M, EBIT increased 91.68% from -$131.24M to -$10.91M, and earnings per share increased from -$1.0063 to -$0.1107.
ZIOPHARM Oncology, Inc. (ZIOP) was upgraded to D from D- on 11/10/2016 due to an increase in the growth index and efficiency index. Net income increased 91.73% from -$131.2M to -$10.85M, EBIT increased 91.68% from -$131.24M to -$10.91M, and earnings per share increased from -$1.0063 to -$0.1107.
D
Sell
8/25/2016Downgrade
ZIOPHARM Oncology, Inc. (ZIOP) was downgraded to D- from D on 8/25/2016 due to a major decline in the efficiency index, solvency index and total return index.
ZIOPHARM Oncology, Inc. (ZIOP) was downgraded to D- from D on 8/25/2016 due to a major decline in the efficiency index, solvency index and total return index.
D
Sell
8/10/2016Upgraded
ZIOPHARM Oncology, Inc. (ZIOP) was upgraded to D from D- on 8/10/2016 due to a major increase in the efficiency index, valuation index and volatility index.
ZIOPHARM Oncology, Inc. (ZIOP) was upgraded to D from D- on 8/10/2016 due to a major increase in the efficiency index, valuation index and volatility index.
D
Sell
3/11/2016Downgrade
ZIOPHARM Oncology, Inc. (ZIOP) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, total return index and valuation index.
ZIOPHARM Oncology, Inc. (ZIOP) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, total return index and valuation index.
D
Sell
2/25/2016Downgrade
ZIOPHARM Oncology, Inc. (ZIOP) was downgraded to D from D+ on 2/25/2016 due to a decline in the efficiency index, volatility index and total return index. Net income declined 47.85% from -$18.17M to -$9.48M, and total capital declined 6.89% from $93.84M to $87.37M.
ZIOPHARM Oncology, Inc. (ZIOP) was downgraded to D from D+ on 2/25/2016 due to a decline in the efficiency index, volatility index and total return index. Net income declined 47.85% from -$18.17M to -$9.48M, and total capital declined 6.89% from $93.84M to $87.37M.
D
Sell
11/3/2015Upgraded
ZIOPHARM Oncology, Inc. (ZIOP) was upgraded to D+ from D on 11/3/2015 due to a large increase in the solvency index, efficiency index and valuation index. Net income increased 27.86% from -$14.21M to -$18.17M.
ZIOPHARM Oncology, Inc. (ZIOP) was upgraded to D+ from D on 11/3/2015 due to a large increase in the solvency index, efficiency index and valuation index. Net income increased 27.86% from -$14.21M to -$18.17M.
D
Sell
2/27/2015Downgrade
ZIOPHARM Oncology, Inc. (ZIOP) was downgraded to D from D+ on 2/27/2015 due to a decline in the efficiency index, solvency index and valuation index. Total capital declined 7.23% from $36.48M to $33.84M.
ZIOPHARM Oncology, Inc. (ZIOP) was downgraded to D from D+ on 2/27/2015 due to a decline in the efficiency index, solvency index and valuation index. Total capital declined 7.23% from $36.48M to $33.84M.
D
Sell
10/31/2014Upgraded
ZIOPHARM Oncology, Inc. (ZIOP) was upgraded to D+ from D on 10/31/2014 due to a major increase in the growth index and efficiency index. Total revenue increased 216.5% from $200 to $633, operating cash flow increased 37.41% from -$7.64M to -$10.49M, and earnings per share increased from -$0.0555 to -$0.0607.
ZIOPHARM Oncology, Inc. (ZIOP) was upgraded to D+ from D on 10/31/2014 due to a major increase in the growth index and efficiency index. Total revenue increased 216.5% from $200 to $633, operating cash flow increased 37.41% from -$7.64M to -$10.49M, and earnings per share increased from -$0.0555 to -$0.0607.
NASDAQ
03/12/2025 4:00PM Eastern
Quotes delayed
